(Q38146710)

29 August 2017

title

New targeted therapies in melanoma (English)

1 reference

29 August 2017

Ragini R Kudchadkar

1

1 reference

29 August 2017

Rene Gonzalez

series ordinal

2

1 reference

29 August 2017

Karl Lewis

series ordinal

3

1 reference

29 August 2017

publication date

1 October 2013

1 reference

29 August 2017

1 reference

29 August 2017

volume

20

1 reference

29 August 2017

issue

4

1 reference

29 August 2017

page(s)

282-288

1 reference

29 August 2017

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Improved survival with MEK inhibition in BRAF-mutated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

A novel transforming gene in a human malignant melanoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

A landscape of driver mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Lack of clinical efficacy of imatinib in metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F107327481302000405

10.1177/107327481302000405

21 January 2018

Identifiers

DOI

0 references

1 reference